Browsing Tag
azenosertib
2 posts
Why Cyclin E1 biomarker targeting may become central to next-generation ovarian cancer therapies
Find out why Zentalis Pharmaceuticals’ Cyclin E1 strategy could reshape ovarian cancer treatment and investor sentiment into 2026.
April 12, 2026
Zentalis Pharmaceuticals reports promising results from Phase 1 trial of azenosertib, gemcitabine combo
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a trailblazer in developing small molecule therapeutics for cancer, has released the final…
May 25, 2024